GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3233)

  • GC74630 structure
    GC74630TI17
    CAS: 1005178-02-8
    Purity: >97.00%

    TI17 는 갑상선 호르몬 수용체 상호작용 단백질 Trip13의 억제제로서 항암 활성을 가지고 있다.

  • GC74668 structure
    GC746683-Methoxy-9H-Carbazole
    CAS: 18992-85-3
    Purity: >99.00%

    3-Methoxy-9H-Carbazole 카스파스-3 활성과 세포의 활성산소 생성을 유도한다.

  • GC74684 structure
    GC74684Topoisomerase II inhibitor 14
    CAS: 305343-00-4
    Purity: >99.00%

    Topoisomerase II inhibitor 14 (화합물 2f) 는 토폴로지아제 II의 강력한 억제제로서 항암 활성을 가지고 있다.

  • GC74719 structure
    GC74719ASC-69
    CAS: 1216665-50-7
    Purity: >99.00%

    ASC-69 (APY69) 는 효과적이고 유망한 PD-1/PD-L1 소분자 억제제입니다.

  • GC74721 structure
    GC74721Geraniol-d6 (Major)
    CAS: 1660976-93-1
    Purity: >95.00%

    Geraniol-d6 (Major) 는 듀테륨 태그의 Geraniol Major입니다.

  • GC74733 structure
    GC74733Methoxyamine-d3 Hydrochloride
    CAS: 110220-55-8
    Purity: >99.00%

    Methoxyamine-d3 Hydrochloride (O-Metldroxylamine-d3)는 Methoxyamine drochloride로 표기된 중수소이다.

  • GC75826 structure
    GC75826YL-5092
    CAS: 3056857-07-6
    Purity: >98.00%

    YL-5092 is a novel, highly selective inhibitor of YTHDC1 (IC 50 =7.4nM; K D =29.6nM).

  • GC78685 structure
    GC78685STING-IN-15
    CAS: 2912492-05-6
    Purity: >98.00%

    STING-IN-15 is a potent STING inhibitor with an IC 50 value of 116nM.

  • GC78764 structure
    GC78764Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
    CAS: 3103526-19-5
    Purity: >97.50%

    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

  • GC78797 structure
    GC78797Bevacizumab vedotin
    Purity: >97.50%

    Bevacizumab vedotin is an antibody-drug conjugate ( ADC ).

  • GC78798 structure
    GC78798NN3201
    Purity: >99.00%

    NN3201 is a c-Kit -targeting antibody-drug conjugate ( ADC ) with high affinity ( K D = 0.19 pM).

  • GC78805 structure
    GC78805Zocilurtatug pelitecan
    CAS: 3058592-88-1
    Purity: >98.00%

    Zocilurtatug pelitecan (ZL-1310) is a blood-brain barrier-penetrating antibody-drug conjugate targeting DLL3.

  • GC78809 structure
    GC78809UCI-14
    CAS: 301312-49-2
    Purity: >98.00%

    UCI-14 is a gltA1/lprQ modulator with in vitro anti-tuberculosis activity against drug-sensitive and multidrug-resistant mycobacteria.

  • GC78810 structure
    GC78810Anisomelic acid
    CAS: 59632-76-7
    Purity: >98.00%

    Anisomelic acid is a human papillomavirus HPV16 E6 and HPV E7 depletor.

  • GC78898 structure
    GC78898JLJ648
    Purity: >98.00%

    JLJ648 is a Gag-Pol dimerizer with antiviral activity.

  • GC78931 structure
    GC78931Viridiflorol
    CAS: 552-02-3
    Purity: >98.00%

    Viridiflorol is an active natural molecule with anti-cancer effect.

  • GC78932 structure
    GC78932MINA53-IN-1
    CAS: 2863676-85-9
    Purity: >99.50%

    MINA53-IN-1 is a selective MINA53 inhibitor with an IC 50 of 1.5 μM.

  • GC78933 structure
    GC78933DB1055
    CAS: 869767-86-2
    Purity: >99.50%

    DB1055 is a HOXA9 inhibitor that competes with HOXA9 binding to DNA (blocking its DNA interaction activity).

  • GC78934 structure
    GC78934CT 32228
    CAS: 521064-34-6
    Purity: >95.00%

    CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β ( LPAAT-β ).

  • GC78935 structure
    GC78935Flucofuron
    CAS: 370-50-3
    Purity: >99.50%

    Flucofuron exhibits high efficacy against trophozoites of both N.

  • GC78936 structure
    GC78936(S)-Edelfosine
    CAS: 83542-43-2
    Purity: >99.50%

    (S)-Edelfosine ((S)-ET-18-OCH3) is the (S)-enantiomer of Edelfosine (ET-18-OCH3).

  • GC78937 structure
    GC78937(1S)-PMMB276
    Purity: >98.00%

    (1S)-PMMB276 is the (1S)-enantiomer of PMMB276.

  • GC78938 structure
    GC78938HF-125
    Purity: >99.50%

    HF-125 is an orally active, highly selective small-molecule inhibitor of Tribbles 2 (TRIB2).

  • GC78939 structure
    GC78939TMLZ-G46
    CAS: 3116767-83-7
    Purity: >98.00%

    TMLZ-G46 is an orally active ZNF207 inhibitor with blood-brain barrier penetration ability, with a K d value of 68 nM.